Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

Area of Science:

• Immunology
• Vaccinology
• Epidemiology

Background:

• Understanding factors influencing vaccine efficacy (VE) is crucial for public health strategies.
• Early COVID-19 vaccine trials provided valuable data on efficacy across different platforms.
• Host and exposure characteristics can potentially modulate vaccine responses.

Purpose of the Study:

• To analyze the impact of baseline host and exposure factors on COVID-19 vaccine efficacy.
• To assess VE consistency across different vaccine platforms (mRNA, viral vector, protein subunit).
• To evaluate VE for both symptomatic and severe COVID-19 in a large, multinational cohort.

Main Methods:

• Cross-protocol analysis of four Phase 3, randomized, placebo-controlled COVID-19 vaccine trials.
• Harmonized data collection from 114,480 participants enrolled between July 2020 and February 2021.
• Univariate and multivariate analyses of VE considering socio-demographic, clinical, and exposure variables.

Main Results:

• Vaccine efficacy against symptomatic COVID-19 showed minimal heterogeneity across diverse baseline characteristics, irrespective of vaccine platform.
• VE against severe COVID-19 (analyzed in one trial) also demonstrated limited heterogeneity.
• No significant influence of baseline host or exposure factors on COVID-19 VE was observed when vaccines were well-matched to circulating strains.

Conclusions:

• COVID-19 vaccine efficacy is robust and not significantly affected by baseline host or exposure characteristics.
• Different vaccine platforms demonstrated comparable efficacy in reducing symptomatic and severe COVID-19.
• These findings support the broad utility of authorized COVID-19 vaccines for vulnerable populations and during variant shifts.